非金属硒联合单克隆抗体或可有效杀灭乳腺癌细胞

  每年大约有25万人被诊断为乳腺癌，与此同时也有300万人饱受乳腺癌的折磨；尽管乳腺癌的治愈率非常高，其5年生存率可以达到89%以上，然而很多患者疾病都会复发；国际乳腺癌防治月上研究人员强调需要加大乳腺癌的研究力度，因为其在美国已成为威胁人们健康的第二大癌症。
  来自德州理工大学的研究人员Julian Spallholz表示，我们一直在研究非金属硒对多种癌症的效应，研究者将硒吸附到主要的化疗药物单克隆抗体上用于治疗乳腺癌，结果显示其可以有效杀灭乳腺癌细胞。大约20%的乳腺癌病人机体中都存在过度表达的生长受体，也就是癌细胞上Her2+受体，其会促进肿瘤无限制生长，而目前临床上的疗法主要针对的是Her2+受体。
临床上的疗法包括单克隆抗体，其被开发用于靶向作用癌细胞，而实际上也证明其可以有效杀灭癌细胞，但是癌症患者往往会对药物产生耐受性；而当研究者将硒细读到单克隆抗体上用于治疗乳腺癌时，结果显示这两者结合可以有效摧毁耐药性患者机体中的乳腺癌细胞。
  Spalholz博士强调，很多研究人员对非金属硒研究了很多年，而本文研究中将硒同单克隆抗体有效吸附结合或许可以进行多种医疗用途来治疗人类疾病，未来硒吸附化学研究获将改变靶向药物的药理学特性。（转化医学网360zhyx.com）
  本文系转化医学网原创翻译整理，欢迎转载！转载请注明来源并附原文链接。谢谢！
转化医学网推荐的新闻阅读：

Almost a quarter of a million people were diagnosed with breast cancer this year, while another 3 million are living with the disease. Although the cure rate for breast cancer is high -- it has an 89 percent 5-year survival rate -- a large number of patients have a recurrence of their cancer. Breast Cancer Awareness Month highlights the continuing research on this type of cancer, the second most common cancer in the United States.
Julian Spallholz, a professor of nutritional sciences at Texas Tech University, has studied the effects of selenium on several types of cancer. His research on attaching selenium to the leading clinical chemotherapeutic monoclonal antibody for a type of breast cancer shows it can more effectively kill the cancer cells, he reports.
About 20 percent of breast cancer patients have overexpressed growth receptors, known as Her2+ receptors, on the cancer cells, which cause uncontrolled tumor growth. The clinical treatment options on the market today focus on those receptors.
This treatment consists of monoclonal antibodies, which scientists have developed to target cancer cells such as Her2+. This has proven to be effective, but a patient's cancer can often develop resistance to the drug.....